Paragon Biosciences

Paragon Biosciences company information, Employees & Contact Information

Paragon is a global life science leader that creates, builds and funds innovative biology-based companies, accelerating scientific breakthroughs to solve some of society's most challenging medical problems.

Company Details

Employees
28
Founded
-
Address
330 N Wabash Ave,
Phone
312-777-3730
Email
in****@****sci.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Chicago, Illinois
Looking for a particular Paragon Biosciences employee's phone or email?

Paragon Biosciences Questions

News

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome - Bain Capital

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome Bain Capital

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study - Yahoo Finance

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study Yahoo Finance

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials - PR Newswire

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials PR Newswire

Paragon’s Portfolio Company – Emalex Biosciences – Raises $250 Million in Series D Financing to Fund Tourette’s Clinical Trial - BOSS Publishing

Paragon’s Portfolio Company – Emalex Biosciences – Raises $250 Million in Series D Financing to Fund Tourette’s Clinical Trial BOSS Publishing

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization - Yahoo Finance

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization Yahoo Finance

Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development - Business Wire

Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development Business Wire

Paragon Biosciences Chairman and CEO Jeff Aronin Earns the 2019 BIG Innovation Award - PR Newswire

Paragon Biosciences Chairman and CEO Jeff Aronin Earns the 2019 BIG Innovation Award PR Newswire

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome - PR Newswire

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome PR Newswire

Top Paragon Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant